Unknown

Dataset Information

0

Class III ?-tubulin counteracts the ability of paclitaxel to inhibit cell migration.

ABSTRACT: Class III ?-tubulin (?3) is associated with tumor aggressiveness, resistance to therapy, and patient relapse. To elucidate its action, we tested ?3's effect on cell migration. Expression of ?3 in HeLa and MCF-7 did not alter the intrinsic rate of cell migration, but it prevented the inhibition of migration by low, nontoxic concentrations of paclitaxel. The effects on cell motility were confirmed in CHO cells with tetracycline regulated expression of ?3. Cell migration and microtubule dynamics were inhibited by similar concentrations of paclitaxel, but required a 5-10 fold higher drug concentration when ?3 was expressed. The directionality of migration was normal in paclitaxel, but cells spent more time in a "paused" state during which there was no net movement. These studies support a model in which paclitaxel inhibits cell migration by suppressing microtubule dynamics and ?3-tubulin counteracts paclitaxel action by maintaining microtubule dynamic activity. The results provide a potential explanation for the aggressiveness of ?3-expressing tumors.

SUBMITTER: Ganguly A 

PROVIDER: S-EPMC3248193 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.

Ganguly Anutosh A   Yang Hailing H   Cabral Fernando F  

Oncotarget 20110501 5

Class III β-tubulin (β3) is associated with tumor aggressiveness, resistance to therapy, and patient relapse. To elucidate its action, we tested β3's effect on cell migration. Expression of β3 in HeLa and MCF-7 did not alter the intrinsic rate of cell migration, but it prevented the inhibition of migration by low, nontoxic concentrations of paclitaxel. The effects on cell motility were confirmed in CHO cells with tetracycline regulated expression of β3. Cell migration and microtubule dynamics we  ...[more]

Similar Datasets

Unknown Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.
| S-EPMC2700829 | biostudies-literature
Unknown Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
| S-EPMC3447874 | biostudies-literature
Unknown Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance.
| S-EPMC2676035 | biostudies-literature
Unknown A transgenic mouse class-III beta tubulin reporter using yellow fluorescent protein.
| S-EPMC2814058 | biostudies-literature
Unknown Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.
| S-EPMC2743364 | biostudies-literature
Unknown Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer.
| S-EPMC5852414 | biostudies-literature
Unknown Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.
| S-EPMC2363042 | biostudies-other
Unknown EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.
| S-EPMC6826612 | biostudies-literature
Unknown Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma.
| S-EPMC7760790 | biostudies-literature
Unknown Class III <i>?</i>-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line.
| S-EPMC6033248 | biostudies-literature